Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
Non Invasive Assessment of Subclinical Atherosclerosis in Relation to Triglyceride-Glucose (TyG) Index and Cardiovascular Risk in Lupus Nephritis a Single Center study_Assuit University
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Renal involvement, known as lupus nephritis (LN), occurs in approximately 40-60% of SLE patients and represents one of the most severe disease manifestations, significantly contributing to morbidity and mortality.Lupus nephritis arises from immune complex deposition in glomerular and tubulointerstitial structures, causing inflammatory and proliferative lesions that can progress to chronic kidney disease or end-stage renal disease. The ISN/RPS classification provides a standardized histopathological framework essential for prognosis and guiding treatment decisions.
In addition to renal complications, patients with SLE and LN are at substantially increased risk of premature cardiovascular disease, which cannot be fully explained by traditional cardiovascular risk factors.Persistent systemic inflammation, endothelial dysfunction, dyslipidemia, and insulin resistance accelerate atherosclerosis in these patients. Subclinical vascular changes, including increased carotid intima-media thickness (CIMT) and carotid plaque formation, often precede overt cardiovascular events, underscoring the importance of early cardiovascular risk assessment The triglyceride-glucose (TyG) index is a validated surrogate marker of insulin resistance, correlating with endothelial dysfunction, subclinical atherosclerosis, and increased CIMT Elevated TyG index may therefore serve as a simple, non-invasive tool for early cardiovascular risk stratification in patients with lupus nephritis
調査の概要
状態
詳細な説明
the study is asingle center observational study will be conducted at Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,_outpatient clinics) including :Full history taking and thorough clinical examination including:
- Demographic Information: Collect data on age, gender, duration of illness, and relevant medical history.
- Body Mass Index (BMI)
- smoking status and Medications history as (corticosteroids, immunosuppressants and anti lipidemic drugs to be excluded)
- Clinical Assessment: patients diagnosed as SLE according to 2019 EULAR/ACR classification criteria. and lupus nephritis (LN) , classified according to the 2018 ISN/RPS classification of lupus nephritis.and Assessment of SLE disease activity according to SLEADI-2K score.
- Laboratory Tests:
- Combelete blood count (CBC)
- Lipid profile ( fasting TGS ,total cholesterol, LDL, HDL, VLDL)
- Fasting blood glucose (mg/Dl)
- Kidney function test (Serum Creatinine ,blood urea nitrogen)
- eGFR
- CRP
- Erthrocyte sedimentation rate (ESR)
- Autoantibody Profiles: ANA, anti-dsDNA
- Complement Levels: C3, C4
- Urinary protein excretion (24-hour urinary protein )
- Homocysteine
- Serum uric acid
Renal biobsy
- Indices calculation:
- Triglyceride-Glucose (TyG) Index
- The CRP_TYG index _- Carotid Ultrasonography
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：nada abdelsalam nada abdelsalam hassan, MSc
- 電話番号：+20 01003562354
- メール：nada011450@med.aun.edu.eg
研究場所
-
-
Assuit
-
Asyut、Assuit、エジプト
- Assuit university hospitals
-
コンタクト：
- Nada Abdelsalam, MSc
- 電話番号：+20 01003562354
- メール：nada011450@med.aun.edu.eg
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Adults aged ≥18 years
Diagnosis of SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus.
- Lupus nephritis , classified according to the 2018 ISN/RPS classification of lupus nephritis.
Exclusion Criteria:
- Established cardiovascular disease (MI, stroke, PAD)
- Diabetes mellitus
- Hypertension
- Patient with CKD
- infections
- other autoimmune diseases
- Pregnancy
- Malignancy
- chronic liver disease
- Dyslipidemia
- Obesity
- Patients on lipid lowering therapy
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
SLE without nephritis
|
|
SLE with nephritis
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
1.Determining whether TyG index independently predicts subclinical atherosclerosis after adjusting for traditional risk factors in patients of systemic lupus erythematosus (SLE) with or without lupus nephritis(LN).
時間枠：baseline (at enrollment)
|
baseline (at enrollment)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- TYG index and CVS risks in LN
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。